FDA to scrutinize unproven cancer drugs after 10-year gap
WASHINGTON – Each year the U.S. approves dozens of new uses for cancer” target=”_blank”>cancer< based on early signs that they can shrink or slow the spread of tumors. But how often do those initial results translate into longer, healthier lives for patients? That seemingly simple question is one of the thorniest debates in medicine. It…